Emplicure AB Interim Report Q3 2022

THIRD QUARTER, JULY-SEPTEMBER 2022

• Net sales amounted to MSEK 0.0 (0.0)
• Operating loss (EBIT) amounted to MSEK -4.5 (-4.0)
• Net loss amounted to MSEK -4.5 (-4.0)
• Net cash flow amounted to MSEK -7.4 (+20.1)
• EPS before and after dilution amounted to SEK -0.17 (-0.20)

JANUARY-SEPTEMBER 2022

• Net sales amounted to MSEK 0.0 (0.1)
• Operating loss (EBIT) amounted to MSEK -20.5 (-11.5)
• Net loss amounted to MSEK -20.5 (-13.3)
• Net cash flow amounted to MSEK -9.1 (+23.4)
• EPS before and after dilution amounted to SEK -0.90 (-1.00)

For additional information, please contact

Håkan Engqvist

CEO
Phone: +46 702 569 500
Email: [email protected]

Erik Magnusson

CFO
Phone: +46 708 565 245
Email: [email protected]

Certified Adviser

Emplicure AB (publ) is listed on the Nasdaq First North Growth Market. Certified Adviser is Erik Penser Bank.

The following documents can be retrieved from beQuoted
Emplicure-Q322 ENG FINAL.pdf

Emplicure develops new and innovative products by combining existing and approved active substances with advanced materials science within ceramic biomaterials. The product portfolio is focused on chronic pain and on abuse-deterrent formulations. The subsidiary Amplicon AB develops consumer products with oral nicotine as the first product. The share is listed on Nasdaq First North Growth Market (EMPLI). Read more at www.emplicure.com

If you want to open the text in your webbrowser click here
______________________________________________________
This information was sent by beQuoted
If you want more information, please go to www.beQuoted.com
To change your subscription, please inform [email protected]

beQuoted Press är en service till Dig som är intresserad av finansiell information. Med beQuoted Press underlättas företagens finansiella kommunikation till Dig och till nyhetsbyråer, aktieägare, placeringsrådgivare och andra intressenter på aktiemarknaden.

Vi hoppas att Du uppskattar denna service.